Imaging AI in New York

aycan is a vendor-neutral medical imaging software provider serving North America for over 25 years. The company specializes in Picture Archiving and Communication Systems (PACS) solutions built on a deconstructed architecture, enabling healthcare organizations to integrate best-of-breed components from multiple vendors while optimizing performance and reducing costs. aycan develops and resells a comprehensive portfolio of DICOM viewers, imaging workstations, PACS archiving systems, and AI-powered diagnostic tools. Core products include the aycan store PACS (scalable on-site and cloud-based archiving with Oracle backend), aycan workstation (general diagnostic reading with 3D/4D post-processing), aycan mammography workstation (optimized for breast imaging and tomosynthesis), MedDream DICOM Viewer (FDA-cleared web-based viewer for multidevice access), and aycan universal thin client viewer (FDA-cleared for primary diagnosis). Recent additions include AI4CMR, a software-as-a-medical-device offering AI-driven cardiac MRI interpretation. aycan integrates complementary partner products including MediReport cardiovascular solutions, EIZO diagnostic monitors, and MedDream viewer updates. The company provides comprehensive services: data migration, system integration, and live remote technical support. ISO 13485 QMS compliant. Serves hospital systems, imaging centers, and radiology groups across the US, Canada, and Mexico. Part of the PARATUS Group, a global healthcare IT collaboration platform.

Koios Medical is a healthcare technology company that develops FDA-cleared, CE-marked AI-powered software for ultrasound image analysis, focusing on early detection of breast and thyroid cancers. The company's proprietary SmartUltrasound® platform (Koios DS™) leverages deep learning algorithms trained on over 500,000 breast lesion ultrasound images to provide clinical decision support for radiologists and sonographers. The platform assists in detecting, classifying, and characterizing suspicious lesions, reducing missed cancers by approximately 10x while improving workflow efficiency. Koios Medical operates on an annual subscription model and partners with major OEMs including GE Healthcare and Philips for distribution across 101+ installation sites in 28 countries. The company's AI-driven approach enhances diagnostic accuracy and supports billable ultrasound procedures, enabling healthcare facilities to streamline cancer detection workflows.

Qure.AI Technologies develops FDA-cleared artificial intelligence software solutions for medical imaging interpretation and follow-up management, focused on early detection and risk stratification of lung nodules and pulmonary pathology. The platform integrates with PACS, EMR, and dictation systems to support radiologists, pulmonologists, and emergency physicians. Core offerings include qXR-LN for lung nodule detection on chest radiographs (6–10mm sensitivity), qCT LN Quant for CT-based volumetric nodule quantification with Lung-RADS and Brock score risk stratification, and qTrack for longitudinal patient follow-up management and care coordination. The company has obtained 26 FDA-cleared indications and holds 40 patents. Products address reimbursement under CMS CPT codes 0721T, 0722T, and 0727T. Qure.AI operates across 107 countries with over 200 peer-reviewed publications and abstracts. The platform serves major healthcare partners including vRad, AstraZeneca, Merck, University Hospitals Cleveland, and Sinai Chicago. The company reported $130M in capital raised and impacts 40M+ lives annually. Solutions emphasize integration into existing clinical workflows without disruption, leveraging LLM-based intelligence for contextual risk assessment beyond traditional NLP.

DESKi develops HeartFocus, an FDA-cleared AI-powered ultrasound software platform that enables clinical-grade cardiac imaging (echocardiography) across diverse care settings without requiring specialized training or dedicated echo labs. The platform combines real-time 3D guidance, on-image AI overlay, auto-recording with quality validation, and live reference examples to help primary care clinicians, nurses, emergency departments, and cardiology teams acquire all ten standard echocardiographic views at diagnostic quality. HeartFocus integrates with DICOM/PACS systems and maintains HIPAA compliance. Clinical evidence published in JACC: Advances demonstrates that novice users, including nurses without prior ultrasound experience, achieved diagnostic-quality imaging across 100% of patients. The company targets primary care, acute care, cardiology, and medical education segments. DESKi has partnered with Butterfly Network for US commercial launch and offers the POCUS HeartFocus Certification—a first-of-its-kind program for AI-guided cardiac imaging. The solution addresses critical gaps in cardiac imaging access, particularly in rural and underserved communities, and supports scalability of cardiac care delivery across the care continuum.

Renalytix is an AI-enabled in vitro diagnostics company specializing in chronic kidney disease (CKD) management, particularly diabetic kidney disease (DKD). The company's flagship product, KidneyIntelX.dkd, combines proprietary AI algorithms with blood-based biomarker analysis, genetic data, and electronic health record integration to generate patient risk stratification scores for progressive kidney function decline. The test received FDA marketing authorization in Q2 2023 and Medicare coverage determination in June 2024. KidneyIntelX enables early identification of high-risk patients with type 2 diabetes and CKD stages 1-3b, allowing clinicians to optimize treatment targeting and resource allocation to slow or prevent disease progression. Renalytix operates CLIA-certified clinical laboratories and partners with major healthcare systems including Mount Sinai Health System, University of Michigan, and Singing River Health System. The company also provides biomarker discovery and drug development support services to pharmaceutical partners. With a focus on shifting kidney disease management from reactive treatment to proactive health optimization, Renalytix addresses a significant public health need affecting over 850 million people globally.

MEDIVIS develops FDA-cleared augmented reality (AR) and surgical navigation software for intraoperative guidance and preoperative planning. The company's flagship product, SurgicalAR, transforms 2D cross-sectional imaging (CT, MRI) into high-fidelity 3D visualizations with real-time surgical navigation and spatial computing capabilities. Primary offerings include: Spine Navigation (FDA-cleared for open and minimally invasive spine procedures), Cranial Navigation (FDA-cleared for EVDs, subdural evacuations, and craniotomies), and Prostate Navigation (research-stage for biopsies and ablations). SurgicalAR features on-premise IT infrastructure with certified gold-standard security, infrared instrument tracking by specialty, photorealistic 3D renderings, model segmentation, livestream imaging to virtual monitors, spatial hand and voice interactions, and an integrated AI agent (Maia, coming soon). Hardware platforms include Medivis PRO (27" touch monitor, 4K graphics, NVIDIA GPU for operating rooms), Medivis CORE (17" portable workstation for ICUs and clinics), and Medivis VIEWER (spatial computing visualization for planning). The company has deployed across 40+ hospitals and medical schools, with 2,000+ surgeries performed using SurgicalAR. Regulatory clearances include FDA 510(k) clearance for spine and cranial modules, CE marking, and Korea FDA clearance. The technology integrates with existing surgical workflows and imaging systems, supporting neurosurgery, orthopedic, and urological specialties. Recognized by TIME Magazine (Best Inventions 2023), Fast Company (Most Innovative 2024), and as Edison Award finalist (2024).

Get-Grin Inc develops integrated digital dentistry solutions designed for orthodontic and general dental practices. The company offers the Grin Scope®, an FDA-registered intraoral camera providing high-definition visibility for chairside and remote diagnosis. The core platform includes the Grin AI 3D Treatment Tracker, which uses patented computer vision to match 2D intraoral scans to 3D treatment plans with tooth-level accuracy. The tracker is appliance-agnostic and integrates with major aligner and digital braces systems. Get-Grin provides virtual care coordination through Grin Care Specialists, enabling remote patient engagement and support. The broader Grin Ecosystem unifies treatment planning, real-time patient progress monitoring, and virtual consultation capabilities. The platform targets solo and multi-location dental practices, DSOs (Dental Service Organizations), and OSOs (Orthodontic Service Organizations). Get-Grin emphasizes doctor-centric design, transparent pricing, and personalization at scale. The company maintains FDA registration for its Scope device and positions itself in the orthodontic technology market with focus on treatment transparency and outcomes tracking.

Imagen is an AI-enabled diagnostic imaging partner delivering teleradiology, on-site imaging equipment, and FDA-cleared AI software to independent practices, hospitals, and health systems nationally. The company operates a network of 95+ board-certified radiologists and sub-specialists across 50 states (active licenses), serving 3.5 million patients in 23 states. Core offerings include: (1) In-Clinic Imaging—permanent, in-office diagnostic imaging equipment with end-to-end support and program deployment; (2) AI-Enabled Interpretations—U.S.-based subspecialized clinicians augmented with proprietary FDA-cleared AI algorithms for improved diagnostic accuracy, consistency, and turnaround time; (3) Advanced Imaging Analytics (RadGap)—AI-driven image and report analytics for payers, providers, and risk-bearing entities to identify and close care gaps. The company positions itself as a partnership model between diagnosticians and ordering physicians, emphasizing 24/7 support, rapid turnaround, and clinical outcomes: 73% reduction in life-threatening misses (chest imaging), 100% improvement in chronic disease identification, and 97% all-time customer retention. Imagen manufactures or deploys diagnostic imaging hardware on-site and develops AI software for image interpretation and population health analytics. FDA clearances include AI algorithms; specific regulatory pathways (510(k), De Novo) not detailed in available content.

Paige.AI is a clinical AI software company specializing in computational pathology for cancer diagnostics and biomarker discovery. The company develops AI-assisted diagnostic applications and foundation models for histopathology analysis, enabling pathologists to detect, subtype, and identify molecular biomarkers from tissue samples. Core product lines include the Paige Prostate Suite, Paige Breast Suite, Paige GI Suite, and Paige PanCancer Suite—all designed to support cancer detection and classification on H&E-stained whole-slide images. The company licenses advanced foundation models (Virchow, Virchow2, Virchow2G, Virchow2G-Mini, and PRISM) to partners for custom AI development in cancer care. Paige Alba is a proprietary co-pilot platform integrating voice and text interfaces with AI diagnostics to streamline pathology workflows. The company provides comprehensive services including custom AI development, regulatory strategy consulting, and commercialization support. Paige's technology is trained cumulatively on over 1.5 million slides and designed to address diagnostic scalability and workload pressures in clinical pathology settings. The firm serves pharmaceutical, life sciences, research, and healthcare provider organizations globally.

AISAP LTD develops FDA-cleared AI diagnostic software for point-of-care ultrasound (POCUS) systems, with a primary focus on cardiac imaging and structural heart disease detection. The company's flagship product, POCUS-OS™, is an all-in-one AI operating system that integrates with existing ultrasound devices from major manufacturers (GE, Philips, Siemens, Samsung, SonoSite, Butterfly, Wisonic, and others) to deliver expert-level cardiac measurements and automated diagnosis at the bedside. The platform includes AI-powered interpretation, structured reporting (reducing reporting time by up to 90%), cloud-based or on-premise PACS functionality, and seamless EMR integration. Clinical applications include early detection of aortic stenosis, mitral regurgitation, tricuspid regurgitation, right ventricular dysfunction, pericardial effusion, and pulmonary embolism risk assessment. The company serves hospitals, health systems, clinics, and emergency departments globally. Research partnerships include Stanford, Mayo Clinic, Inova, Jefferson Health, and others. AISAP emphasizes workflow efficiency, reduced length of stay, improved diagnostic accuracy for non-cardiologists, and increased billing capture (up to 95% billable encounters). The platform operates on flexible deployment (on-premise to cloud architecture) and includes QA/accreditation tools for quality standardization. FDA clearance status confirmed on website; CE and ISO compliance inferred from regulatory context but not explicitly stated.

Ezra AI is a medical imaging company offering AI-powered full-body MRI and CT screening services for early cancer detection and disease prevention. The company operates a direct-to-consumer model, providing comprehensive imaging scans that examine up to 13 organs in as little as 22 minutes, radiation-free. Ezra's primary service offerings include the MRI Scan ($999), which scans the head, neck, abdomen, and pelvis for signs of cancer and hundreds of other conditions; the MRI Scan with Spine ($1,699), which adds comprehensive spine imaging for lesions, tumors, degenerative changes, and structural abnormalities; and the MRI Scan with Skeletal and Neurological Assessment ($3,999), which includes brain age analysis, musculoskeletal evaluation (hips/knees), and MR angiography of head and neck vessels. The company also offers specialized CT scans: a Heart CT Scan ($349) measuring coronary artery calcium for cardiovascular risk assessment, and a Lung CT Scan ($399) for early lung cancer detection and pulmonary abnormalities. All scans are designed to be eligible for HSA/FSA reimbursement. Ezra has partnered with Function, a membership wellness program, to provide members with credits toward advanced imaging. The company emphasizes early cancer detection, noting that early-stage cancer has an 80% survival rate versus less than 20% for late-stage disease. Scans are administered at imaging centers and include physician-reviewed results with actionable clinical findings. Flexible monthly payment plans are available, and couples discount programs are offered.

Fluidda NV is a global leader in Functional Respiratory Imaging (FRI), a proprietary technology that combines high-resolution CT (HRCT) scans with Computational Fluid Dynamics (CFD) and artificial intelligence to advance respiratory healthcare. The company operates as both a Contract Research Organization (CRO) and a clinical decision-support partner, serving pharmaceutical, biotech, and healthcare organizations in drug development, medical device validation, and patient diagnosis and monitoring. Fluidda's FRI technology enables detailed regional lung functionality assessment, personalized treatment optimization, and accelerated clinical trial design for respiratory conditions including asthma, COPD, cystic fibrosis, and other pulmonary diseases. The platform provides clinicians and researchers with visualization and quantitative analysis of airflow patterns and regional lung physiology beyond standard spirometry, supporting precision medicine approaches. Fluidda recently joined Banook, a global clinical trial services organization, enhancing its capacity to deliver end-to-end respiratory drug and device development solutions. The company serves healthcare systems, pulmonologists, radiologists, and respiratory researchers worldwide, with demonstrated applications in real-world clinical practice and public health initiatives. Fluidda's technology reduces clinical trial timelines, improves cost-effectiveness, and supports evidence-based treatment selection for better patient outcomes in respiratory disease management.

DeepTek Medical Imaging is an India-based artificial intelligence software company specializing in radiology workflow automation and diagnostic support. The company develops cloud-based AI platforms and clinical decision support tools for medical imaging. Primary products include Augmento Enterprise (FDA-cleared AI deployment platform and cloud PACS with advanced viewer for CT/MR/PET-CT imaging and comprehensive analytics), Genki (AI-powered lung health and tuberculosis screening solution with integrated RIS and VIM), and Augmento X-Ray (chest X-ray reporting automation tool with automated segregation and structured clinical report generation). The company serves radiology departments, diagnostic imaging centers, and public health organizations globally, with particular strength in TB and respiratory screening applications. DeepTek holds US FDA clearance for Augmento Enterprise and Augmento X-Ray, CE MDR Class IIb certification for chest X-ray AI, and WHO recommendation for TB screening. The platform integrates with major cloud providers (AWS, Google Cloud, Microsoft Azure) and partners with leading PACS vendors and healthcare systems across Asia, Africa, and North America. Founded by radiologists and data scientists, DeepTek emphasizes responsible AI with post-deployment surveillance capabilities.

AEYE Health is an FDA-cleared AI diagnostic platform specializing in autonomous diabetic retinopathy screening from retinal images. The company offers AEYE-DS, the only fully autonomous AI solution for point-of-care diabetic retinopathy detection requiring a single image per eye, enabling primary care physicians, pharmacies, and home care providers to perform rapid screening without specialist referral. AEYE Health also develops AEYE-X, a broader retinal imaging diagnostic platform for detecting multiple eye and systemic diseases. Operating with handheld cameras (Aurora AEYE with Optomed) and robotic tabletop systems (integrated with Topcon Healthcare), the company targets the >40 million Americans with diabetes, achieving 92-93% sensitivity and >99% image success rates. The solution is CPT 92229 reimbursable and addresses critical gaps in diabetic retinopathy care access.

Firefly Neuroscience is an FDA-cleared neurodiagnostic software platform company specializing in objective brain health assessment and early detection of neurological and psychiatric conditions. The company's flagship product, Evoke™ System, combines quantitative EEG (qEEG) and event-related potentials (ERP) analysis with proprietary AI and machine learning to translate complex brain signals into clinically actionable insights. Built on a proprietary database of over 191,000 EEG and ERP sessions from individuals aged 12–85, Evoke™ enables clinicians to identify deviations in brain function, differentiate overlapping conditions (depression, anxiety, ADHD, concussion, cognitive decline, neurodegenerative disorders), and track treatment response with precision. The platform delivers age-matched normative comparisons and cloud-based reporting to support earlier diagnosis, more targeted treatment planning, and personalized care protocols. Firefly serves healthcare practitioners seeking measurable, data-driven neurological assessment and supports CNS drug developers through biomarker development and companion diagnostic collaborations.

Optain Health is an AI-enabled medical device and software company specializing in non-invasive retinal imaging technology for preventive disease screening and detection. The company offers an integrated turnkey solution comprising a portable automatic fundus camera and proprietary Software as a Medical Device (SaMD) that leverages AI algorithms to analyze full-color retinal images in real-time. Optain's platform screens for diabetic retinopathy, glaucoma, age-related macular degeneration, and cardiovascular disease risk, enabling clinicians to identify referable conditions and risk-stratify patients efficiently. The technology supports three stakeholder segments: healthcare providers (streamlined workflow and standardized care), patients (detailed health insights), and insurers (population health screening and risk stratification). Founded in 2023 and backed by $26 million in Series A funding, Optain combines clinical expertise with advanced AI to democratize access to specialized eye disease screening while reducing diagnostic delays and improving health equity across diverse populations.

Aidoc is a healthcare AI software company founded in 2016, providing clinical decision support solutions built on its proprietary aiOS™ platform. The company delivers AI-powered medical imaging analysis and clinical intelligence tools across radiology, cardiology, neurovascular, and vascular care specialties. Aidoc's algorithms automatically analyze medical imaging (primarily CT scans) to detect acute pathologies, identify incidental findings, and prioritize critical cases for rapid clinical intervention. The platform integrates with hospital workflows to improve notification time-to-treatment, enhance care team coordination, and optimize patient management across departments. Serving over 1,600 medical centers globally and analyzing imaging for approximately 45 million patients annually, Aidoc enables healthcare systems to cover approximately 75% of their patient populations with AI-assisted clinical decision support. Key clinical applications include stroke detection and door-to-puncture time reduction, pulmonary embolism prioritization, cardiac disease measurement, and vascular pathology management.

MRIguidance develops BoneMRI, a medical imaging software solution that generates 3D CT-like images of bone structures derived from standard MRI scans. The technology eliminates the need for ionizing radiation exposure while providing diagnostic-quality bone visualization, eliminating duplicate imaging procedures and reducing patient hospital visits. BoneMRI integrates seamlessly with clinical workflows through automatic image reconstruction and PACS forwarding, compatible with major MRI scanner platforms from GE, Siemens, and Philips. The solution serves orthopedic surgery, spine surgery, and surgical navigation applications across cervical, thoracic, lumbar spine, and pelvic anatomies. Intended for adult, adolescent, and pediatric patient populations, BoneMRI supports diagnostic imaging, surgical navigation and planning, and research applications. The company holds trademark registrations in the US, UK, and EU. Recent product updates include stitching functionality and expanded scanner compatibility. Founded as a European company and operating a US entity, MRIguidance markets to academic medical centers and specialty surgical hospitals.

Parable Health is a mobile, computer vision-powered asynchronous telemedicine platform specializing in chronic woundcare management. The platform enables clinicians to measure, monitor, and manage complex patient populations through automated volumetric measurements, quantitative and qualitative assessments, and comprehensive risk scoring. Parable integrates with EHR systems and clinical IT infrastructure to automate complex workflows, standardize care protocols, and scale clinical expertise across broader patient populations. The platform leverages machine learning on millions of comprehensive wound assessments to deliver actionable clinical insights and reduces human error and variability in documentation. Parable supports both post-acute and inpatient wound management, as well as ambulatory follow-up scenarios including plastic surgery, orthopedics, and dermatology. The platform operates on familiar mobile devices with store-and-forward telemedicine capabilities, enabling remote collaboration and reducing excessive labor, transportation, and supply costs.